{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-25-000119","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.480904+00:00","generated_at":"2026-05-20T03:01:25.470437+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zentalis reports azenosertib triplet achieves 35% ORR and 5.8-month PFS in BRAFi-naïve mCRC at ASCO 2025","bullets":["ORR of 35.3% (12/34 confirmed responses) in BRAF inhibitor-naïve patients; median DoR 6.0 months (95% CI 4.4-NE).","Median PFS of 5.8 months (95% CI 3.9-9.2) in BRAF-naïve subset; prior BRAFi-treated patients had 1.8 months.","MTD set at azenosertib 300 mg + encorafenib 75 mg + cetuximab 500 mg/m2; no DLTs at MTD, manageable safety.","Most common TRAEs were asthenia (36%) and decreased appetite (34%); grade 3/4 asthenia occurred in 11% across all doses.","Efficacy exceeded historical encorafenib + cetuximab doublet (BEACON: ORR 20%, PFS 4.2 months) in BRAF-naïve mCRC."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-25-000119","json":"https://secwatch.observer/filing/0001725160-25-000119.json","markdown":"https://secwatch.observer/filing/0001725160-25-000119.md","text":"https://secwatch.observer/filing/0001725160-25-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000119/0001725160-25-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000119/zntl-20250531.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:01:25.470437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}